Sorafenib combined with percutaneous radiofrequency ablation for the treatment of medium-sized hepatocellular carcinoma

European Review for Medical and Pharmacological Sciences

Volumn 19, Issue 2, 2015, Pages 247-255

  Kan, X ^a   Jing, Y ^a   Wan, Q Y ^b   Pan, J C ^c   Han, M ^a   Yang, Y ^a   Zhu, M ^d   Wang, Q ^a   Liu, K H ^a  

^a JINAN INFECTIOUS DISEASE HOSPITAL   (China)

^b Department of Internal Medicine Qihe County People's Hospital   (China)

^c SHANDONG UNIVERSITY   (China)

^d SHANDONG UNIVERSITY   (China)

Author keywords

Hepatocellular carcinoma; Medium sized; Radiofrequency ablation; Sorafenib

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA FETOPROTEIN; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; SORAFENIB; VASCULOTROPIN; ANTINEOPLASTIC AGENT; CARBANILAMIDE DERIVATIVE; NICOTINAMIDE;

ADJUVANT THERAPY; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALOPECIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CANCER ADJUVANT THERAPY; CANCER GROWTH; CANCER RECURRENCE; CANCER SIZE; CANCER SURVIVAL; DIARRHEA; DISTANT METASTASIS; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEMALE; FEVER; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; RADIOFREQUENCY ABLATION; RADIOFREQUENCY ABLATION DEVICE; SIDE EFFECT; SURVIVAL TIME; TREATMENT OUTCOME; ANALOGS AND DERIVATIVES; CARCINOMA, HEPATOCELLULAR; CATHETER ABLATION; CONTROLLED STUDY; KAPLAN MEIER METHOD; LIVER NEOPLASMS; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PROCEDURES; RANDOMIZED CONTROLLED TRIAL; TUMOR RECURRENCE;

ADULT; ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; CATHETER ABLATION; COMBINED MODALITY THERAPY; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NIACINAMIDE; PHENYLUREA COMPOUNDS; TREATMENT OUTCOME;

EID: 84938885303     PISSN: 11283602     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. FERLAY J, SHIN HR, BRAY F, FORMAN D, MATHERS C, PARKIN DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127: 2893-2917.
2. TANG ZY. Perspective of clinical onology from the viewpoint of liver cancer studies. Tumor 2009; 29: 1-4. (in Chinese).
3. YANG HI, LU SN, LIAW YF, YOU SL, SUN CA, WANG LY, HSIAO CK, CHEN PJ, CHEN DS, CHEN CJ. Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med 2002; 347: 168-174.
4. BRUIX J, SHERMAN M. Management of hepatocellular carcinoma. Hepatology 2005; 42: 1208-1236.
5. PARK KW, PARK JW, CHOI JI, KIM TH, KIM SH, PARK HS, LEE WJ, PARK SJ, HONG EK, KIM CM. Survival analysis of 904 patients with hepatocellular carcinoma in a hepatitis B virus-endemic area. J Gastroenterol Hepatol 2008; 23: 467-473.
6. BRUIX J, SHERMAN M. Management of hepatocellular carcinoma: An update. Hepatology 2011; 53: 1020-1022.
7. LIN SM, LIN CJ, LIN CC, HSU CW, CHEN YC. Radiofrequence ablation improves prognosis compared with ethanol injection for hepatocellular carcinoma < or = 4 cm. Gastroenterology 2004; 127: 1714-1723.
8. LENCIONI R, CROCETTI L. Local-regional treatment of hepatocellular carcinoma. Radiology 2012; 262: 43-58.
9. LENCIONI RA, ALLGAIER HP, CIONI D, OLSCHEWSKI M, DEIBERT P, CROCETTI L, FRINGS H, LAUBENBERGER J, ZUBER I, BLUM HE, BARTOLOZZI C. Small hepatocellular carcinoma in cirrhosis: randomized comparison of radiofrequency ablation versus percutaneous ethanol injection. Radiology 2003; 228: 235-240.
10. MORIMOTO M, NUMATA K, KONDOU M, NOZAKI A, MORITA S, TANAKA K. Midterm outcomes in patients with intermediate-sized hepatocellular carcinoma a randomized controlled trial for determining the efficacy of radiofrequency ablation combined with transcatheter arterial chemoembolization. Cancer 2010; 116: 5452-5460.
11. GERMANI G, PLEGUEZUELO M, GURUSAMY K, MEYER T, ISGRÒ G, BURROUGHS AK. Clinical outcomes of radiofrequency ablation, percutaneous alcohol and acetic acid injection for hepatocellular carcinoma: A meta-analysis. J Hepatol 2010; 52: 380- 388.
12. WILHELM SM, CARTER C, TANG L, WILKIE D, MCNABOLA A, RONG H, CHEN C, ZHANG X, VINCENT P, MCHUGH M, CAO Y, SHUJATH J, GAWLAK S, EVELEIGH D, ROWLEY B, LIU L, ADNANE L, LYNCH M, AUCLAIR D, TAYLOR I, GEDRICH R, VOZNESENSKY A, RIEDL B, POST LE, BOLLAG G, TRAIL PA. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involves in tumor progression and angiogenesis. Cancer Res 2004; 64: 7099-7109.
13. CHENG AL, KANG YK, CHEN Z, TSAO CJ, QIN S, KIM JS, LUO R, FENG J, YE S, YANG TS, XU J, SUN Y, LIANG H, LIU J, WANG J, TAK WY, PAN H, BUROCK K, ZOU J, VOLIOTIS D, GUAN Z. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: A phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009; 10: 25-34.
14. CHEN MS, LI JQ, ZHENG Y, GUO RP, LIANG HH, ZHANG YQ, LIN XJ, LAN WY. A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma. Ann Surg 2006; 243: 321-328.
15. NG KK, POON RT, LO CM, YUEN J, TSO WK, FAN ST. Analysis of recurrence pattern and its influence on survival outcome after radiofrequency ablation of hepatocellular carcinoma. J Gastrointest Surg 2009; 12: 183-191.
16. LLOVET JM, RICCI S, MAZZAFERRO V, HILGARD P, GANE E, BLANC JF, DE-OLIVEIRA AC, SANTORO A, RAOUL JL, FORNER A, SCHWARTZ M, PORTA C, ZEUZEM S, BOLONDI L, GRETEN TF, GALLE PR, SEITZ JF, BORBATH I, HÄUSSINGER D, GIANNARIS T, SHAN M, MOSCOVICI M, VOLIOTIS D, BRUIX J. SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378- 390.
17. YAU T, CHAN P, NG KK, CHOK SH, CHEUNG TT, FAN ST, POON RT. Phase 2 open-label study of single agent sorafenib in treating advanced hepatocellular carcinoma in a hepatitis B-endemic Asian population: presence of lung metastasis predicts poor response. Cancer 2009; 115: 428-436.
18. LAU WY, LEUNG TW, YU SC, HO SK. Percutaneous local ablative therapy for hepatocellular carcinoma: A review and look into the future. Ann Surg 2003; 237: 171-179.
19. LAU WY, LAI EC. The current role of radiofrequency ablation in the management of hepatocellular carcinoma: A systematic review. Ann Surg 2009; 249: 20-25.
20. LLOVET JM, BRUIX J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 2003; 37: 429-442.
21. LIVRAGHI T, MÄKISALO H, LINE PD. Treatment options in hepatocellular carcinoma today. Scand J Surg 2011; 100: 22-29.
22. CHUNG YH, HAN G, YOON JH, YANG J, WANG J, SHAO GL, KIM BI, LEE TY, CHAO Y. Interim analysis of START: Study in Asia of the combination of TACE (Transcatheter arterial chemoembolization) with sorafenib in patients with Hepatocellular Carcinoma Trial. Int J Cancer 2013; 132: 2448-2458.
23. QU XD, CHEN CS, WANG JH, YAN ZP, CHEN JM, GONG GQ, LIU QX, LUO JJ, LIU LX, LIU R, QIAN S. The efficacy of TACE combined sorafenib in ad vanced stages hepatocellullar carcinoma. BMC Cancer 2012; 12: 263.
24. ZHAO Y, WANG WJ, GUAN S, LI HL, XU RC, WU JB, LIU JS, LI HP, BAI W, YIN ZX, FAN DM, ZHANG ZL, HAN GH. Sorafenib combined with transarterial chemoembolization for the treatment of advanced hepatocellular carcinoma: A large-scale multicenter study of 222 patients. Ann Oncol 2013; 24: 1786-1792.
25. KEATING GM, SANTORO A. Sorafenib: A review of its use in advanced hepatocellular carcinoma. Drugs 2009; 69: 223-240.
26. ROBERTS PJ, DER CJ. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene 2007; 26: 3291- 3310.